HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.

Abstract
We analysed the factors influencing the efficacy of peripheral blood stem cell (PBSC) collection in patients with lymphoma. Sixty-six patients underwent initial PBSC collection following mobilization with chemotherapy plus recombinant granulocyte colony-stimulating factor (300 microg/d). Patients were mobilized with one of two chemotherapy regimens, either cyclophophamide (3 g/m2 or 4 g/m2) (n = 50) or ifosphamide, etoposide and epirubicin (IVE; n = 16). The target of collecting > 2.0 x 10(6) CD34+ cells/kg was achieved in 43/66 (65%) patients with a median of two apheresis procedures. The IVE plus G-CSF mobilization regimen gave a significantly higher median yield of CD34+ cells (8.62 x 10(6)/kg) compared with cyclophosphamide plus G-CSF (3.59 x 10(6)/kg) (P = 0.045). The median yield of CD34+ cells per leukapheresis was almost twice as high in patients receiving IVE (1.94 x 10(6)/kg) compared to cyclophosphamide (1.03 x 10(6)/kg) (P = 0.035). In a univariate analysis of the factors affecting mobilization, the subtype of lymphoma (high-grade NHL) and the mobilization regimen were the only factors associated with high CD34+ cell yield. However, in a multivariate analysis of factors affecting mobilization including age, lymphoma subtype, previous chemotherapy and radiotherapy, only the use of the IVE protocol was predictive of a high yield of CD34+ cells. In 13 patients undergoing a second mobilization procedure the use of IVE was associated with a significantly higher yield of CD34+ cells compared to cyclophosphamide; three patients who failed cyclophosphamide plus G-CSF mobilization were able to proceed to transplantation following successful mobilization with IVE + G-CSF. These results demonstrate that IVE is a highly effective mobilization regimen which is superior to cyclophophamide and has the benefit of being effective salvage therapy for lymphoma patients.
AuthorsI G McQuaker, A P Haynes, C Stainer, S Anderson, N H Russell
JournalBritish journal of haematology (Br J Haematol) Vol. 98 Issue 1 Pg. 228-33 (Jul 1997) ISSN: 0007-1048 [Print] England
PMID9233591 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Drug Combinations
  • Granulocyte Colony-Stimulating Factor
  • Epirubicin
  • Etoposide
  • Cyclophosphamide
  • Ifosfamide
Topics
  • Adult
  • Aged
  • Cyclophosphamide (therapeutic use)
  • Drug Combinations
  • Epirubicin (therapeutic use)
  • Etoposide (therapeutic use)
  • Female
  • Granulocyte Colony-Stimulating Factor (therapeutic use)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Hematopoietic Stem Cells (drug effects)
  • Humans
  • Ifosfamide (therapeutic use)
  • Lymphoma (therapy)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Transplantation Conditioning (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: